Portal de investigación
INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER
Datos básicos
- Protocolo:
- CB16/12/00481
- EUDRACT:
- NCT:
- Centro:
- Año de incio:
- Año de finalización:
- 2020
Documentos
- No hay documentos
Grupos y Plataformas de I+D+i
Financiadores - Promotores
Resultados del Ensayo Clínico
Biocompatibility and internalization assessment of bare and functionalised mesoporous silica nanoparticles
Garrido-Cano, I; (...); Martinez-Manez, R
Article. 10.1016/j.micromeso.2020.110593. 2021
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer.
Adam-Artigues, A; (...); Cejalvo, J M
Article. 10.1016/j.esmoop.2020.100039. 2021
Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.
Garrido-Cano, Iris; (...); Eroles, Pilar
Article. 10.3390/ijms21197427. 2020
Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia.
Ballester, Sandra; (...); Eroles, Pilar
Article. 10.3390/genes11060686. 2020
Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma.
Sanegre, S; (...); Noguera, R
Article. 10.3389/fcell.2021.670185. 2021
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
Lluch, A; (...); Albanell, J
Article. 10.1016/j.ejca.2019.07.003. 2019
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
Oltra, SS; (...); Martinez, MT
Article. 10.3390/cancers12020412. 2020
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
Torres-Ruiz, Sandra; (...); Eroles, Pilar
Article. 10.3390/ijms24043601. 2023
Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness.
Sonzini, Giorgia; (...); Noguera, Rosa
Article. 10.3389/fcell.2022.1052098. 2022
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Perez-Nunez, Ivan; (...); Celia-Terrassa, Toni
Article. 10.1038/s43018-022-00339-4. 2022
MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma.
Pattanayak, Birlipta; (...); Eroles, Pilar
Article. 10.3389/fonc.2020.01661. 2020
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano, Iris; (...); Eroles, Pilar
Article. 10.1007/s10555-021-09992-0. 2022
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+Breast Cancer
Cabello, Paula; (...); Eroles, Pilar
Article. 10.3390/cancers15072138. 2023
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.
Torres-Ruiz, S; (...); Eroles, P
Article. 10.1038/s41420-024-02128-7. 2024
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
Casadevall, David; (...); Albanell, Joan
Article. 10.1158/1541-7786.MCR-21-0545. 2022
Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool.
Garrido-Cano, Iris; (...); Martinez-Manez, Ramon
Article. 10.1021/acssensors.0c02222. 2021
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Guardia, Cristina; (...); Albanell, Joan
Article. 10.1158/1078-0432.CCR-20-2915. 2021
RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines
Albanell-Fernandez, M; (...); Ribas, G
Article. 10.3390/cancers15010069. 2023
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues, A; (...); Cejalvo, JM
Article. 10.1126/sciadv.abk2746. 2022
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
Tormo, E; (...); Eroles, P
Article. 10.1038/s41598-019-41472-y. 2019
